Antiplaquettaires et hemorragie peroperatoire. [Antiplatelet drugs and intraoperative hemorrhage]

Détails

ID Serval
serval:BIB_3F3D3FF38B59
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Antiplaquettaires et hemorragie peroperatoire. [Antiplatelet drugs and intraoperative hemorrhage]
Périodique
Revue Médicale Suisse
Auteur(s)
Chassot  P. G., Delabays  A., Ravussin  P., Spahn  D. R.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
11/2006
Volume
2
Numéro
88
Pages
2684-7
Notes
English Abstract
Journal Article
Review --- Old month value: Nov 22
Résumé
Antiplatelet drugs and intraoperative haemorrhage Current literature demonstrates that there is less risk involved in maintaining anti-aggregant therapy (which might imply to transfuse more the patients), than in stopping it, which then increases dangerously the risk of coronary thrombosis. Aspirin, as a secondary preventive drug, should not be interrupted. Clopidogrel is essential for protection against thrombosis in areas where the endothelium is not intact. Unless there is a high hemorrhagic risk in closed cavities (intracranial surgery), clopidogrel should not be interrupted. Furthermore, any surgical intervention increasing the coagulability of the platelets, it seems particularly dangerous to stop such medication perioperatively.
Mots-clé
Algorithms Aspirin/*therapeutic use Blood Loss, Surgical/*physiopathology Coronary Thrombosis/*prevention & control Drug Therapy, Combination Humans Intraoperative Period Platelet Aggregation Inhibitors/*therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors Risk Assessment Ticlopidine/*analogs & derivatives/therapeutic use
Pubmed
Création de la notice
28/01/2008 10:48
Dernière modification de la notice
03/03/2018 16:24
Données d'usage